Viatris (VTRS) Stock
Fundamentals
Recent news

Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy?
Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy?
VTRS

3 Generic Drug Stocks to Watch Amid Improving Industry Trends
3 Generic Drug Stocks to Watch Amid Improving Industry Trends
VTRS

Here's Why Viatris (VTRS) is a Strong Value Stock
Here's Why Viatris (VTRS) is a Strong Value Stock
VTRS

VTRS Q2 Earnings Beat, Revenues Rise 5% as Greater China Sales Jump
VTRS Q2 Earnings Beat, Revenues Rise 5% as Greater China Sales Jump
VTRS
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.63 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy?
Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy?
VTRS

3 Generic Drug Stocks to Watch Amid Improving Industry Trends
3 Generic Drug Stocks to Watch Amid Improving Industry Trends
VTRS

Here's Why Viatris (VTRS) is a Strong Value Stock
Here's Why Viatris (VTRS) is a Strong Value Stock
VTRS

VTRS Q2 Earnings Beat, Revenues Rise 5% as Greater China Sales Jump
VTRS Q2 Earnings Beat, Revenues Rise 5% as Greater China Sales Jump
VTRS

Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics
Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics
VTRS

Viatris (VTRS) Beats Q2 Earnings and Revenue Estimates
Viatris (VTRS) Beats Q2 Earnings and Revenue Estimates
VTRS

Viatris (VTRS) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Viatris (VTRS) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
VTRS

Viatris Gears Up to Report Q2 Earnings: What's in the Cards?
Viatris Gears Up to Report Q2 Earnings: What's in the Cards?
VTRS

Viatris (VTRS) Q2 Earnings Preview: What's in the Cards?
Viatris (VTRS) Q2 Earnings Preview: What's in the Cards?
VTRS

FDA Showdown Week: CAPR, NRXP, REPL And MRNA Face Make-Or-Break Regulatory Decisions
FDA Showdown Week: CAPR, NRXP, REPL And MRNA Face Make-Or-Break Regulatory Decisions
VTRS
About Viatris
Viatris Inc. is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a growing portfolio of biosimilars and a variety of over-the-counter consumer products.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Scott Andrew Smith Ph.D. | CEO & Director | 1962 |
| Mr. Andrew Enrietti | Chief Administrative & Transformation Officer | 1985 |
| Dr. Corinne M. Le Goff M.B.A., Pharm.D. | Chief Commercial Officer | 1965 |
| Mr. Paul B. Campbell | Interim CFO, Chief Accounting Officer & Corporate Controller | 1967 |
| Mr. Ramkumar V. Rayapureddy | Chief Information Officer | — |
| Mr. William Szablewski C.F.A. | Head of Investor Relations & Capital Markets | — |
| Mr. Matthew Joseph Maletta | Chief Legal Officer | 1972 |
| Ms. Lara Ramsburg | Chief People & Corporate Affairs Officer | — |
| Mr. Philippe Martin | Chief R&D Officer | 1976 |
| Mr. Peter McCormick | Chief Supply Officer | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
4 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -2.2 | -1.8 | -10.9 | +11.9 | ||||||||
| 2022 | +5.3 | -26.9 | +7.2 | -4.5 | +20.2 | -13.3 | -9.5 | -1.1 | -11.0 | +16.2 | +7.6 | -1.0 |
| 2023 | +6.9 | -7.0 | -14.9 | -2.9 | -2.2 | +8.7 | +6.5 | +5.2 | -8.6 | -11.4 | +2.9 | +15.6 |
| 2024 | +3.3 | +4.2 | -5.2 | -3.1 | -8.9 | +0.5 | +13.9 | +1.0 | -2.4 | +1.0 | +12.7 | -5.7 |
| 2025 | -9.2 | -16.4 | -6.6 | -2.1 | +3.8 | +2.8 | -4.8 | +19.8 | -6.3 | +2.7 | +1.5 | +16.4 |
| 2026 | +5.1 | +9.1 | -13.9 | +9.6 | +8.1 | +0.4 | +8.5 | -6.4 | +7.2 |
Corporate actions
Upcoming
No upcoming corporate actions for VTRS



